MCID: ANP006
MIFTS: 46

Anaplastic Ependymoma

Categories: Neuronal diseases, Rare diseases

Aliases & Classifications for Anaplastic Ependymoma

MalaCards integrated aliases for Anaplastic Ependymoma:

Name: Anaplastic Ependymoma 54 60 56 6 74

Characteristics:

Orphanet epidemiological data:

60
anaplastic ependymoma
Inheritance: Not applicable; Age of onset: Adolescent,Adult,Childhood;

Classifications:

Orphanet: 60  
Rare neurological diseases


External Ids:

UMLS via Orphanet 75 C0280788
Orphanet 60 ORPHA251646
UMLS 74 C0280788

Summaries for Anaplastic Ependymoma

NIH Rare Diseases : 54 Anaplastic ependymoma is a type of ependymoma, which is a tumor that forms when cells in the central nervous system (including the brain and spinal cord) begin to multiply rapidly. An ependymoma is anaplastic if the cells grow very quickly and are significantly unusual in shape. Ependymomas can occur at any age. When ependymomas occur in children, they are more frequently located in the brain (intracranial). Ependymomas are more often found in the spinal cord of affected adults. Symptoms of an anaplastic ependymoma depend on the age of the person and the size and location of the tumor but may include headaches, nausea, vision changes, seizures, and changes in mood or personality.  The exact cause of an anaplastic ependymoma is not known, but it is thought that certain changes (acquired pathogenic variants, also known as somatic mutations ) in specific genes in some cells of the body allow the cells to begin growing quickly. A diagnosis of anaplastic ependymoma is generally suspected based on imaging with MRI or CT scan. The diagnosis can be confirmed with a biopsy of the tumor or when the tumor is removed (resected). Treatment for anaplastic ependymoma begins with surgery to remove as much of the tumor as possible. Radiation therapy is also recommended for people with anaplastic ependymoma.

MalaCards based summary : Anaplastic Ependymoma is related to subependymoma and malignant ependymoma, and has symptoms including seizures, vomiting and headache. An important gene associated with Anaplastic Ependymoma is MUC1 (Mucin 1, Cell Surface Associated), and among its related pathways/superpathways are Neuroscience and Cellular senescence (KEGG). The drugs Carboplatin and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and bone, and related phenotypes are behavior/neurological and normal

Related Diseases for Anaplastic Ependymoma

Diseases related to Anaplastic Ependymoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 209)
# Related Disease Score Top Affiliating Genes
1 subependymoma 32.2 GFAP SYP
2 malignant ependymoma 31.8 GFAP NF2 RELA
3 benign ependymoma 31.3 GFAP NF2 SYP
4 ependymoma 31.2 GFAP MUC1 NF2 RELA S100B SYP
5 secretory meningioma 30.6 MUC1 VIM
6 ependymoblastoma 30.1 GFAP VIM
7 ganglioglioma 30.0 GFAP S100B SYP
8 myxopapillary ependymoma 29.7 GFAP MUC1 S100B VIM
9 angiocentric glioma 29.6 GFAP S100B SYP VIM
10 hydrocephalus 29.4 GFAP PTEN SYP
11 meningioma, familial 29.3 GFAP NF2 PTEN SYP
12 gliosarcoma 29.2 GFAP PTEN S100B VIM
13 malignant adult ependymoma 11.3
14 intraneural perineurioma 10.4 MUC1 S100B
15 moyamoya disease 2 10.4 LOC100294362 RNF213
16 meningeal melanocytoma 10.4 MUC1 S100B
17 tubular adenocarcinoma 10.4 MUC1 SYP
18 gastric tubular adenocarcinoma 10.4 MUC1 SYP
19 mixed ductal-endocrine carcinoma 10.4 MUC1 SYP
20 ectopic cushing syndrome 10.4 S100B SYP
21 olfactory neuroblastoma 10.4 S100B SYP
22 localized hypertrophic neuropathy 10.4 MUC1 S100B
23 sclerosing perineurioma 10.4 MUC1 S100B
24 reticular perineurioma 10.4 MUC1 S100B
25 non-functioning pituitary adenoma 10.3 MUC1 S100B
26 functioning pituitary adenoma 10.3 MUC1 S100B
27 mucinous cystadenocarcinoma 10.3 MUC1 VIM
28 epithelioid malignant peripheral nerve sheath tumor 10.3 MUC1 S100B
29 chondroid chordoma 10.3 MUC1 VIM
30 pericardial mesothelioma 10.3 MUC1 VIM
31 sinonasal undifferentiated carcinoma 10.3 MUC1 SYP
32 middle ear adenoma 10.3 MUC1 SYP
33 hidradenocarcinoma 10.3 S100B VIM
34 aggressive digital papillary adenocarcinoma 10.3 MUC1 S100B
35 fibrolamellar carcinoma 10.3 SYP VIM
36 granulosa cell tumor of the ovary 10.3 SYP VIM
37 hypoganglionosis 10.3 S100B SYP
38 ovarian small cell carcinoma 10.3 MUC1 SYP
39 spiradenoma 10.3 MUC1 S100B
40 myopericytoma 10.3 RELA S100B
41 traumatic brain injury 10.3 GFAP S100B
42 rosette-forming glioneuronal tumor 10.3 S100B SYP
43 bednar tumor 10.3 S100B VIM
44 central nervous system benign neoplasm 10.3 GFAP SYP
45 cystic teratoma 10.3 GFAP SYP
46 medullomyoblastoma 10.3 GFAP SYP
47 pilomyxoid astrocytoma 10.3 GFAP SYP
48 myxosarcoma 10.3 MDM2 SYP
49 cerebellar liponeurocytoma 10.3 GFAP SYP
50 supratentorial primitive neuroectodermal tumor 10.3 S100B SYP

Graphical network of the top 20 diseases related to Anaplastic Ependymoma:



Diseases related to Anaplastic Ependymoma

Symptoms & Phenotypes for Anaplastic Ependymoma

UMLS symptoms related to Anaplastic Ependymoma:


seizures, vomiting, headache, nausea

MGI Mouse Phenotypes related to Anaplastic Ependymoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.56 GFAP MDM2 NF2 PTEN RNF213 S100B
2 normal MP:0002873 9.17 GFAP MDM2 PTEN RELA RNF213 S100B

Drugs & Therapeutics for Anaplastic Ependymoma

Drugs for Anaplastic Ependymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 216)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
2
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
3
Vincristine Approved, Investigational Phase 3,Phase 2 2068-78-2, 57-22-7 5978
4
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
5
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
6
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
7
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
8
Dopamine Approved Phase 3,Early Phase 1,Not Applicable 62-31-7, 51-61-6 681
9
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
10 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
11
Emodepside Investigational, Vet_approved Phase 3 155030-63-0
12 Central Nervous System Depressants Phase 3,Phase 1,Phase 2
13 Etoposide phosphate Phase 3,Phase 2
14 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
15 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
16 Keratolytic Agents Phase 3,Phase 1,Phase 2
17 Alkylating Agents Phase 3,Phase 2,Phase 1
18 Antimitotic Agents Phase 3,Phase 1,Phase 2
19 Immunologic Factors Phase 3,Phase 2,Phase 1
20 Topoisomerase Inhibitors Phase 3,Phase 2
21 Podophyllotoxin Phase 3,Phase 1,Phase 2 518-28-5
22 Antirheumatic Agents Phase 3,Phase 2
23 Dermatologic Agents Phase 3,Phase 1,Phase 2
24 Antineoplastic Agents, Phytogenic Phase 3,Phase 1,Phase 2
25 Cola Phase 3,Phase 1
26 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
27 Analgesics, Opioid Phase 3
28 Anesthetics Phase 3
29 Anesthetics, Intravenous Phase 3
30 Narcotics Phase 3
31 Adjuvants, Anesthesia Phase 3
32 Analgesics Phase 3,Phase 2,Phase 1
33 Liver Extracts Phase 3,Phase 2,Phase 1
34 Anesthetics, General Phase 3
35 Cholinesterase Inhibitors Phase 3,Phase 2
36 Nootropic Agents Phase 3,Phase 2
37 Neurotransmitter Agents Phase 3,Phase 2,Early Phase 1,Not Applicable
38 Cholinergic Agents Phase 3,Phase 2
39 Central Nervous System Stimulants Phase 3,Phase 2
40 Dopamine Agents Phase 3,Early Phase 1,Not Applicable
41 Dopamine Uptake Inhibitors Phase 3
42 Dexmethylphenidate Hydrochloride Phase 3
43 Neurotransmitter Uptake Inhibitors Phase 3
44
Sargramostim Approved, Investigational Phase 2,Phase 1 123774-72-1, 83869-56-1
45
Lenograstim Approved, Investigational Phase 2,Phase 1 135968-09-1
46
Mesna Approved, Investigational Phase 2 3375-50-6 598
47
Carmustine Approved, Investigational Phase 1, Phase 2,Phase 2 154-93-8 2578
48
Ethanol Approved Phase 1, Phase 2 64-17-5 702
49
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
50
Everolimus Approved Phase 2,Phase 1 159351-69-6 70789204 6442177

Interventional clinical trials:

(show top 50) (show all 88)
# Name Status NCT ID Phase Drugs
1 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
2 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
3 Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma Recruiting NCT01096368 Phase 3 Carboplatin;Cisplatin;Cyclophosphamide;Etoposide;Vincristine Sulfate Liposome
4 Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
5 Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
6 Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma Unknown status NCT00027846 Phase 2 carboplatin;cyclophosphamide;etoposide;vincristine sulfate;Mesna
7 Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm Unknown status NCT00009854 Phase 1, Phase 2 carmustine in ethanol
8 Everolimus for Children With Recurrent or Progressive Ependymoma Completed NCT02155920 Phase 2 Everolimus
9 Etoposide Plus Cisplatin in Treating Patients With Recurrent Ependymomas Completed NCT00002876 Phase 2 cisplatin;etoposide
10 Combination Chemotherapy Plus Radiation Therapy in Treating Adult Patients With Brain Cancer Completed NCT00003309 Phase 2 cisplatin;cyclophosphamide;etoposide;vincristine sulfate
11 Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma Completed NCT00058123 Phase 2 poly ICLC
12 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2 bevacizumab;placebo
13 Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma Completed NCT00826241 Phase 2 Temozolomide;Lapatinib
14 Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma Completed NCT01026493 Phase 1, Phase 2 temozolomide 60 mg x 21 days;temozolomide 75 mg x 21 days;ABT-888 20 mg x 21 days;ABT-888 40 mg x 21 days;Temozolomide 150 mg x 5 days;ABT-888 40 mg x 5 days
15 Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors Completed NCT01032200 Phase 2 Armodafinil
16 Levetiracetam or Pregabalin in Treating Seizures in Patients Undergoing Chemotherapy and/or Radiation Therapy For Primary Brain Tumors Completed NCT00629889 Phase 2 levetiracetam;pregabalin
17 Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors Completed NCT00541138 Phase 2 carboplatin;tamoxifen citrate;topotecan hydrochloride
18 Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma Completed NCT00498927 Phase 2 temozolomide
19 Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma Completed NCT00352521 Phase 2 bevacizumab;irinotecan
20 Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas Completed NCT00274755 Phase 2 chemotherapy
21 Combination Chemotherapy Followed by Radiation Therapy in Treating Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma Completed NCT00006258 Phase 2 cisplatin;cyclophosphamide;etoposide;methotrexate;vincristine sulfate
22 Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer Completed NCT00014573 Phase 2 carmustine;cisplatin;cyclophosphamide;paclitaxel
23 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary Brain Tumors Completed NCT00003478 Phase 1, Phase 2
24 Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor Completed NCT00070161 Phase 2 donepezil hydrochloride
25 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers Completed NCT00002752 Phase 1, Phase 2
26 Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
27 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
28 Carboplatin and Bevacizumab for Recurrent Ependymoma Recruiting NCT01295944 Phase 2 Carboplatin;Bevacizumab
29 Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma Recruiting NCT03727841 Phase 2 Marizomib
30 Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas Active, not recruiting NCT01478321 Phase 2 Temozolomide
31 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
32 Antineoplaston Therapy in Treating Patients With Ependymoma Terminated NCT00003479 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
33 Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma Terminated NCT01095094 Phase 2 ritonavir;lopinavir
34 Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors Terminated NCT01836549 Phase 2 imetelstat sodium
35 Photodynamic Therapy in the Treatment of Malignant Intracranial Tumors Withdrawn NCT00243490 Phase 2
36 Functional Magnetic Resonance Imaging and 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Treating Patients With Newly Diagnosed Brain Tumors Withdrawn NCT00005083 Phase 2
37 Enzastaurin and Temozolomide in Treating Patients With Primary Gliomas Unknown status NCT00516607 Phase 1 enzastaurin hydrochloride;temozolomide
38 Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas Unknown status NCT00083096 Phase 1 lonafarnib;temozolomide
39 Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors Unknown status NCT00002647 Phase 1 verteporfin
40 Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2 Completed NCT01082926 Phase 1
41 Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas Completed NCT02186509 Phase 1 Alisertib
42 Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases Completed NCT01234740 Phase 1 bafetinib
43 Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors Completed NCT01131234 Phase 1 Gamma-Secretase Inhibitor RO4929097;Cediranib Maleate
44 Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Completed NCT00030498 Phase 1 erlotinib hydrochloride
45 RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Completed NCT01119599 Phase 1 Gamma-Secretase Inhibitor RO4929097;Temozolomide
46 Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma Completed NCT01480050 Phase 1 temozolomide;Mibefradil
47 Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma Completed NCT00730613 Phase 1
48 A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors Completed NCT00784914 Phase 1 temsirolimus
49 Carmustine in Treating Patients With Recurrent Malignant Glioma Completed NCT00004028 Phase 1 carmustine
50 Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment Completed NCT00544284 Phase 1 bortezomib;temozolomide

Search NIH Clinical Center for Anaplastic Ependymoma

Genetic Tests for Anaplastic Ependymoma

Anatomical Context for Anaplastic Ependymoma

MalaCards organs/tissues related to Anaplastic Ependymoma:

42
Brain, Spinal Cord, Bone, Bone Marrow, Liver, Pineal, Kidney

Publications for Anaplastic Ependymoma

Articles related to Anaplastic Ependymoma:

(show top 50) (show all 106)
# Title Authors Year
1
Microsurgical Resection of Anaplastic Ependymoma of the Cerebellopontine Angle in an Adult: 3-Dimensional Operative Video. ( 30295880 )
2019
2
Sudden Unexpected Death in a Child From an Anaplastic Ependymoma. ( 30958386 )
2019
3
Anaplastic ependymoma arising from the lower segment of the uterine corpus: Case report and literature review. ( 31060102 )
2019
4
A Case of Recurrent Supratentorial Extraventricular Anaplastic Ependymoma in Adult. ( 31062531 )
2019
5
Rapid autopsy of a patient with recurrent anaplastic ependymoma. ( 28942746 )
2018
6
RELA fusion-positive anaplastic ependymoma: molecular characterization and advanced MR imaging. ( 29063976 )
2018
7
Adult Supratentorial Extraventricular Anaplastic Ependymoma: Therapeutic Approach and Clinical Review. ( 29492136 )
2018
8
Pediatric Isolated Cortical (Ectopic) Anaplastic Ependymoma. ( 29492147 )
2018
9
Radiation necrosis following proton therapy successfully treated by low-dose bevacizumab in a patient with relapsed anaplastic ependymoma. ( 29667785 )
2018
10
Pineal Anaplastic Ependymoma With Multifocal Intradural Extramedullary Metastases on MRI and 18FDG-PET. ( 30080187 )
2018
11
Preoperative and intraoperative perfusion magnetic resonance imaging in a RELA fusion-positive anaplastic ependymoma: A case report. ( 30105138 )
2018
12
Pediatric Case of Li-Fraumeni Syndrome Complicated with Supratentorial Anaplastic Ependymoma. ( 30196175 )
2018
13
Supratentorial extraventricular WHO grade III (anaplastic) ependymoma 17 years after total removal of WHO grade II ependymoma of the fourth ventricle. ( 27215793 )
2017
14
"Drop" Metastases from an Operated Case of Intracranial Anaplastic Ependymoma Identified on Fluoro-2-deoxyglucose Positron Emission Tomography/Computed Tomography. ( 28242994 )
2017
15
Hormonal based treatment of ovarian anaplastic ependymoma with anastrozole. ( 28393092 )
2017
16
Anaplastic Ependymoma With Ganglionic Differentiation: Report of a Rare Case and Implications in Diagnosis. ( 28554236 )
2017
17
Spinal cord anaplastic ependymoma induced by radiation treatment of breast cancer. ( 28555490 )
2017
18
Encouraging option of multi-staged gross total resection for a C11orf-RelA fusion-positive supratentorial anaplastic ependymoma. ( 28831588 )
2017
19
Multifocal intradural extramedullary anaplastic ependymoma of the spine. ( 29354756 )
2017
20
Temozolomide Treatment for Pediatric Refractory Anaplastic Ependymoma with Low MGMT Protein Expression. ( 26305586 )
2016
21
Anaplastic Ependymoma in a Child With Sickle Cell Anemia: A Case Report Highlighting Treatment Challenges for Young Children With Central Nervous System Tumors and Underlying Vasculopathy. ( 26488903 )
2016
22
Re-irradiation of recurrent anaplastic ependymoma using radiosurgery or fractionated stereotactic radiotherapy. ( 26682738 )
2016
23
Erratum to: Re-irradiation of recurrent anaplastic ependymoma using radiosurgery or fractionated stereotactic radiotherapy. ( 26820979 )
2016
24
Radiation-induced anaplastic ependymoma mimicking a skull base meningioma: A case report. ( 26893630 )
2016
25
Pure extra-axial supratentorial anaplastic ependymoma with no cortical attachment: A rare case. ( 26954823 )
2016
26
Brain Tumor in an In Vitro Fertilization-Facilitated Pregnancy: Fourth Ventricle Anaplastic Ependymoma in the Second Trimester. ( 27330925 )
2016
27
Magnetic resonance imaging findings of extraventricular anaplastic ependymoma: A report of 11 cases. ( 27602137 )
2016
28
Angiocentric glioma transformed into anaplastic ependymoma: Review of the evidence for malignant potential. ( 27742374 )
2016
29
Supratentorial extraventricular anaplastic ependymoma with extracranial metastasis. ( 25455735 )
2015
30
Anaplastic ependymoma of spinal cord presented with low back pain. ( 25843250 )
2015
31
Paediatric intracranial anaplastic ependymoma: the role of multiple surgical resections for disease relapse in maintaining quality of life and prolonged survival. ( 25871983 )
2015
32
An 11 Year Old Child with a Right Parieto-Occipital Lesion. Anaplastic Ependymoma (WHO Grade III) with Granular Cell Features. ( 26086056 )
2015
33
Role of Evaluating MGMT Status and 1p36 Deletion in Radiosurgery-Induced Anaplastic Ependymoma That Rapidly and Completely Resolved by Temozolomide Alone: Case Report and Review of the Literature. ( 26251808 )
2015
34
An extraneural primary anaplastic ependymoma at the subcutaneous inguinal region: Report of a rare case. ( 26549094 )
2015
35
Supratentorial extraventricular anaplastic ependymoma in an adult with repeated intratumoral hemorrhage. ( 23546851 )
2014
36
Treatment of ovarian anaplastic ependymoma by an aromatase inhibitor. ( 24413241 )
2014
37
Supratentorial extraventricular anaplastic ependymoma in a child. ( 24623545 )
2014
38
Anaplastic ependymoma of the third ventricle. ( 24643478 )
2014
39
Ectopic cortical anaplastic ependymoma: an unusual case report and literature review. ( 25051164 )
2014
40
Supratentorial extraventricular anaplastic ependymoma presenting with repeated intratumoral hemorrhage. ( 25408930 )
2014
41
Radiation-induced anaplastic ependymoma with a remarkable clinical response to temozolomide: a case report. ( 23163298 )
2013
42
Anaplastic ependymoma with holocordal and intracranial meningeal carcinomatosis and holospinal bone metastases. ( 23422903 )
2013
43
Anaplastic ependymoma with ependymoblastic multilayered rosettes. ( 23791209 )
2013
44
A headache presenting in the emergency room, a clinical manifestation of an unfortunate diagnosis (grade III left frontal anaplastic ependymoma with 1p deletion). ( 23912654 )
2013
45
Supratentorial gross-totally resected non-anaplastic ependymoma: population based patterns of care and outcomes analysis. ( 24085643 )
2013
46
Cisplatin and temozolomide combination in the treatment of supratentorial anaplastic ependymoma. ( 24192541 )
2013
47
Cortical anaplastic ependymoma with significant desmoplasia: a case report and literature review. ( 24455359 )
2013
48
Extra and intramedullary anaplastic ependymoma in thoracic spinal cord. ( 24757483 )
2013
49
Anaplastic ependymoma simulating glioblastoma in the cerebrum of an adult. ( 21833575 )
2012
50
Tandem high-dose chemotherapy and autologous stem cell transplantation for anaplastic ependymoma in children younger than 3 years of age. ( 22081297 )
2012

Variations for Anaplastic Ependymoma

ClinVar genetic disease variations for Anaplastic Ependymoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 PALB2 NM_024675.3(PALB2): c.3249G> C (p.Glu1083Asp) single nucleotide variant Conflicting interpretations of pathogenicity rs147045425 GRCh38 Chromosome 16, 23607965: 23607965
2 PALB2 NM_024675.3(PALB2): c.3249G> C (p.Glu1083Asp) single nucleotide variant Conflicting interpretations of pathogenicity rs147045425 GRCh37 Chromosome 16, 23619286: 23619286
3 RUNX1 NM_001754.4(RUNX1): c.155T> A (p.Met52Lys) single nucleotide variant Uncertain significance rs200431130 GRCh37 Chromosome 21, 36259336: 36259336
4 RUNX1 NM_001754.4(RUNX1): c.155T> A (p.Met52Lys) single nucleotide variant Uncertain significance rs200431130 GRCh38 Chromosome 21, 34887039: 34887039
5 RNF213 NM_001256071.2(RNF213): c.12841C> T (p.Arg4281Trp) single nucleotide variant other rs765980348 GRCh37 Chromosome 17, 78346864: 78346864
6 RNF213 NM_001256071.2(RNF213): c.12841C> T (p.Arg4281Trp) single nucleotide variant other rs765980348 GRCh38 Chromosome 17, 80373064: 80373064

Expression for Anaplastic Ependymoma

Search GEO for disease gene expression data for Anaplastic Ependymoma.

Pathways for Anaplastic Ependymoma

GO Terms for Anaplastic Ependymoma

Cellular components related to Anaplastic Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuron projection GO:0043005 8.92 NF2 PTEN SYP VIM

Biological processes related to Anaplastic Ependymoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.78 MDM2 PTEN RELA S100B
2 cellular response to hypoxia GO:0071456 9.54 MDM2 PTEN S100B
3 response to morphine GO:0043278 9.49 MDM2 RELA
4 regulation of neuronal synaptic plasticity GO:0048168 9.46 S100B SYP
5 intermediate filament organization GO:0045109 9.43 GFAP VIM
6 astrocyte development GO:0014002 9.4 GFAP VIM
7 negative regulation of neuron projection development GO:0010977 9.33 GFAP MDM2 VIM
8 response to inorganic substance GO:0010035 9.32 PTEN RELA
9 Bergmann glial cell differentiation GO:0060020 9.26 GFAP VIM
10 long-term synaptic potentiation GO:0060291 9.13 GFAP PTEN S100B
11 intermediate filament-based process GO:0045103 8.62 GFAP VIM

Molecular functions related to Anaplastic Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.17 GFAP MDM2 PTEN RELA S100B SYP

Sources for Anaplastic Ependymoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....